Carna Biosciences, Inc. (4572.T)
JPY 282.0
(0.0%)
JPY 282.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.45 Billion JPY | 19.37% |
| 2022 | 1.21 Billion JPY | -35.44% |
| 2021 | 1.88 Billion JPY | 99.97% |
| 2020 | 941.19 Million JPY | -68.63% |
| 2019 | 2.99 Billion JPY | 495.21% |
| 2018 | 503.99 Million JPY | 15.86% |
| 2017 | 435.01 Million JPY | -21.92% |
| 2016 | 557.17 Million JPY | -57.13% |
| 2015 | 1.29 Billion JPY | 243.08% |
| 2014 | 378.8 Million JPY | -29.77% |
| 2013 | 539.35 Million JPY | 79.51% |
| 2012 | 300.45 Million JPY | -23.06% |
| 2011 | 390.5 Million JPY | 5.55% |
| 2010 | 369.96 Million JPY | -21.49% |
| 2009 | 471.24 Million JPY | 25.14% |
| 2008 | 376.58 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 98.81 Million JPY | -26.37% |
| 2024 Q1 | 134.2 Million JPY | -84.45% |
| 2023 Q1 | 178.33 Million JPY | -26.69% |
| 2023 Q2 | 239.55 Million JPY | 34.33% |
| 2023 Q4 | 862.94 Million JPY | 408.32% |
| 2023 FY | 1.45 Billion JPY | 19.37% |
| 2023 Q3 | 169.76 Million JPY | -29.13% |
| 2022 Q2 | 244.29 Million JPY | -52.3% |
| 2022 FY | 1.21 Billion JPY | -35.44% |
| 2022 Q4 | 243.26 Million JPY | 12.9% |
| 2022 Q1 | 512.16 Million JPY | -61.82% |
| 2022 Q3 | 215.46 Million JPY | -11.8% |
| 2021 Q4 | 1.34 Billion JPY | 646.27% |
| 2021 FY | 1.88 Billion JPY | 99.97% |
| 2021 Q1 | 192.6 Million JPY | -14.89% |
| 2021 Q2 | 168.36 Million JPY | -12.58% |
| 2021 Q3 | 179.75 Million JPY | 6.76% |
| 2020 Q4 | 226.3 Million JPY | 4.85% |
| 2020 Q3 | 215.83 Million JPY | 6.61% |
| 2020 Q2 | 202.46 Million JPY | -31.74% |
| 2020 Q1 | 296.59 Million JPY | 3.05% |
| 2020 FY | 941.19 Million JPY | -68.63% |
| 2019 FY | 2.99 Billion JPY | 495.21% |
| 2019 Q4 | 287.82 Million JPY | -15.65% |
| 2019 Q2 | 2.24 Billion JPY | 1680.86% |
| 2019 Q1 | 126.04 Million JPY | 31.23% |
| 2019 Q3 | 341.24 Million JPY | -84.8% |
| 2018 Q2 | 143 Million JPY | -1.94% |
| 2018 Q3 | 119.1 Million JPY | -16.71% |
| 2018 Q1 | 145.83 Million JPY | 22.02% |
| 2018 FY | 503.99 Million JPY | 15.86% |
| 2018 Q4 | 96.04 Million JPY | -19.36% |
| 2017 Q3 | 101.3 Million JPY | 21.93% |
| 2017 Q2 | 83.08 Million JPY | -36.64% |
| 2017 Q1 | 131.11 Million JPY | -21.03% |
| 2017 FY | 435.01 Million JPY | -21.92% |
| 2017 Q4 | 119.51 Million JPY | 17.98% |
| 2016 Q3 | 84.96 Million JPY | -46.04% |
| 2016 Q1 | 148.72 Million JPY | -21.0% |
| 2016 FY | 557.17 Million JPY | -57.13% |
| 2016 Q4 | 166.02 Million JPY | 95.42% |
| 2016 Q2 | 157.45 Million JPY | 5.87% |
| 2015 FY | 1.29 Billion JPY | 243.08% |
| 2015 Q3 | 95.04 Million JPY | -87.27% |
| 2015 Q4 | 188.25 Million JPY | 98.07% |
| 2015 Q2 | 746.88 Million JPY | 177.21% |
| 2015 Q1 | 269.42 Million JPY | 209.9% |
| 2014 Q2 | 85.15 Million JPY | -24.84% |
| 2014 FY | 378.8 Million JPY | -29.77% |
| 2014 Q1 | 113.3 Million JPY | -20.7% |
| 2014 Q3 | 93.4 Million JPY | 9.69% |
| 2014 Q4 | 86.94 Million JPY | -6.92% |
| 2013 Q1 | 118.67 Million JPY | 34.17% |
| 2013 Q4 | 142.87 Million JPY | -12.69% |
| 2013 Q3 | 163.64 Million JPY | 43.36% |
| 2013 Q2 | 114.15 Million JPY | -3.82% |
| 2013 FY | 539.35 Million JPY | 79.51% |
| 2012 Q3 | 60.86 Million JPY | -23.01% |
| 2012 Q4 | 88.45 Million JPY | 45.32% |
| 2012 FY | 300.45 Million JPY | -23.06% |
| 2012 Q2 | 79.06 Million JPY | 9.69% |
| 2012 Q1 | 72.07 Million JPY | -17.13% |
| 2011 Q1 | 115.01 Million JPY | 36.85% |
| 2011 Q3 | 84.87 Million JPY | -18.11% |
| 2011 Q4 | 86.98 Million JPY | 2.49% |
| 2011 FY | 390.5 Million JPY | 5.55% |
| 2011 Q2 | 103.64 Million JPY | -9.89% |
| 2010 FY | 369.96 Million JPY | -21.49% |
| 2010 Q1 | 100.82 Million JPY | -15.97% |
| 2010 Q3 | 65.01 Million JPY | -45.86% |
| 2010 Q4 | 84.04 Million JPY | 29.27% |
| 2010 Q2 | 120.08 Million JPY | 19.11% |
| 2009 FY | 471.24 Million JPY | 25.14% |
| 2009 Q1 | 110.44 Million JPY | 0.0% |
| 2009 Q2 | 114.08 Million JPY | 3.3% |
| 2009 Q3 | 126.73 Million JPY | 11.08% |
| 2009 Q4 | 119.98 Million JPY | -5.32% |
| 2008 FY | 376.58 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | 22.894% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | -1706.336% |
| GNI Group Ltd. | 22.43 Billion JPY | 93.533% |
| Linical Co., Ltd. | 3.77 Billion JPY | 61.607% |
| Trans Genic Inc. | 2.24 Billion JPY | 35.508% |
| MEDINET Co., Ltd. | 98.25 Million JPY | -1376.404% |
| Soiken Holdings Inc. | 2.48 Billion JPY | 41.564% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | -12.222% |
| AnGes, Inc. | -3.06 Billion JPY | 147.323% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 916.235% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 84.99% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | -180.421% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | -1207.361% |
| CanBas Co., Ltd. | -984 Million JPY | 247.418% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | -270.335% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | 12.412% |
| Chiome Bioscience Inc. | 398.59 Million JPY | -263.927% |
| Kidswell Bio Corporation | 1.03 Billion JPY | -39.563% |
| PeptiDream Inc. | 17.21 Billion JPY | 91.575% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | -4639.735% |
| Ribomic Inc. | -10.5 Million JPY | 13912.569% |
| SanBio Company Limited | -14.5 Million JPY | 10101.351% |
| Healios K.K. | 108 Million JPY | -1243.144% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | 425494.721% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 2556.722% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | 96038.889% |
| StemRIM | -44.34 Million JPY | 3370.865% |
| CellSource Co., Ltd. | 3.18 Billion JPY | 54.455% |
| FunPep Company Limited | -680.28 Million JPY | 313.233% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -1994.723% |
| Stella Pharma Corporation | 217.29 Million JPY | -567.561% |
| TMS Co., Ltd. | -6.95 Million JPY | 20971.885% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | -361.149% |
| Cuorips Inc. | 9.63 Million JPY | -14961.738% |
| K Pharma,Inc. | 910 Million JPY | -59.406% |
| Takara Bio Inc. | 25.45 Billion JPY | 94.302% |
| ReproCELL Incorporated | 1.1 Billion JPY | -31.309% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | -21.383% |
| StemCell Institute Inc. | 1.57 Billion JPY | 7.95% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 12.97% |
| CellSeed Inc. | 107.15 Million JPY | -1253.736% |